Relatlimab

瑞拉利单抗

Report date: 2026/05/21 20:00:22

Base Information

Drug NameRelatlimab
Drug Alias NameONO-4482BMS-986016
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionLymphocyte activation gene 3 protein inhibitorsAntibody-dependent cell-mediated cytotoxicity (ADCC) effects
TargetsLymphocyte activation gene 3 protein
Therapy Area/IndicationsUveal melanomaBrain metastasesSkin Melanoma +[41] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[38] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol Myers Squibb SrlcompanyBristol-Myers Squibb (China) Investment Co LtdInstitut Bergonié +[14] 
Inactive CompaniesMultiple Myeloma Research Consortium LlcOno Pharmaceutical Co Ltd
Active IndicationsUveal melanomaBrain metastasesSkin Melanoma +[37] 
Inactive IndicationsFemale Urogenital Diseases and Pregnancy ComplicationsMale Urogenital DiseasesMultiple Myeloma +[4] 

Other Information

ATC CodeN/A
Related LinksN/A